We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Cirius Therapeuticsannounced today that it presented a late-breaking poster describing the activity of the company's lead drug MSDC-0602K in a three-dimensional bioprinted human tissue model of NASH